Cost of goods sold analysis and recommendations to reduce costs of co-packaged mifepristone-misoprostol for medical abortion.
Lester ChineryChadia AllaouidineAlessandra TomazziniMelanie LarsonAhmet Metin GülmezogluPublished in: Reproductive health (2020)
It is feasible to lower the cost of quality-assured combi-packs, through reducing mifepristone API cost and selection of the manufacturing location. However, manufacturers need to be incentivised to achieve WHO pre-qualification with a carefully built business case and require support in identifying and sourcing competitively priced material and manufacturing products to the necessary standard.
Keyphrases